Skip to main content
OpenTrials
Completed

NCT Number: NCT00055393

Bupropion in the Treatment of Pathological Gambling

This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Roy J. and Lucille A. Carver College of Medicine, University of Iowa

Iowa City, Iowa, 52242, United States

About this study

As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.

Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);
  • Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);
  • Receive a score of 5 or more on the South Oaks Gambling Screen (SOGS);
  • Have PG for at least one year;
  • Have had at least 2 or more gambling episodes during the 2-week screening period;
  • Speak standard English;
  • Be able to give written informed consent.

Exclusion criteria

  • Evidence of current (past 3 months) substance misuse;
  • Had a Hamilton Depression Rating Scale (HDRS)27 score of 18 or more (or a score on item 1 of greater than 2;
  • Had a current eating disorder (except binge eating disorder);
  • Had any history of seizures, or suicidal or aggressive behavior;
  • Had a urine drug screen positive for stimulants, opiates, hallucinogens, or phencyclidine;
  • Had a current or past psychotic disorder, bipolar disorder, or significant cognitive disorder;
  • Received monoamine oxidase inhibitors within 3 weeks of randomization, long acting phenothiazine within 3 months of randomization,fluoxetine within 4 weeks of randomization, or other psychotropic drugs within 2 weeks of randomization;
  • Had prior exposure to bupropion;
  • Were engaged in individual, group, or couples psychotherapy during the 2 weeks before randomization, (except Gamblers Anonymous).

Treatment and study plan

bupropion

Drug

18 subjects in this randomly controlled double blind study received bupropion.

Placebo

Drug

21 subjects received Placebo.

Sponsors and collaborators

Lead sponsor

University of Iowa

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Official study title

Bupropion Versus Placebo in the Treatment of Pathological Gambling

Important dates

Study start
2002
Primary completion
2005
Study completion
2006
First posted
Mar 3, 2003
Registry last updated
Mar 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.